Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All astegolimab studies
..
Feedback
Home
c19early.org COVID-19 treatment researchAstegolimabAstegolimab (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 astegolimab studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -31% 1 264 Improvement, Studies, Patients Relative Risk Mortality -31% 1 264 RCTs -31% 1 264 Late -31% 1 264 Astegolimab for COVID-19 c19early.org October 2025 Favorsastegolimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 study c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 mortality result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 serious outcome c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) 1% 0.99 [0.74-1.33] no recov. 130 (n) 134 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Late treatment 1% 0.99 [0.74-1.33] 130 (n) 134 (n) 1% lower risk All studies 1% 0.99 [0.74-1.33] 130 (n) 134 (n) 1% lower risk 1 astegolimab COVID-19 recovery result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 Randomized Controlled Trial c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 RCT mortality result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 peer reviewed studies c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control COVASTIL Waters (DB RCT) 1% 0.99 [0.74-1.33] no recov. 130 (n) 134 (n) Astegolimab COVID-19 outcomes c19early.org October 2025 Favors astegolimab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0